Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1733 participants.

Also called NCT02791230

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,733 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02791230
  • EudraCT 2016-000868-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hong Kong SAR China, Italy, Japan, Netherlands, Spain, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02791230. Allocation not applicable; no masking; primary purpose treatment. Start 2016-06-13 (actual); primary completion 2023-10-26 (actual). Results posted on 2025-02-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Condition
Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention (Drug)
Tafamidis
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02791230
Content hash
d69fc68f20d47695927d1d5cd2dd07865f03bdd3280acad4692b1867a310af62